Recently, a functional polymorphism in the NFKB1 gene promoter (À94ins/del ATTG) has been identified and associated with chronic inflammatory diseases. The aim of this study was to analyze the association of NFKB1 polymorphism with susceptibility to and phenotype of Graves' disease (GD). The initial case-control association study, performed in a Polish-Warsaw cohort (388 GD patients and 688 controls), was followed by the two replication studies performed in Polish-Gliwice and JapaneseKurume cohorts (198 GD patients and 194 controls, and 424 GD patients and 222 controls, respectively). The frequency of the À94del ATTG (D) allele was increased in GD compared to controls in Warsaw cohort. This finding was replicated in Gliwice cohort. Combining both Polish-Caucasian cohorts showed that the NFKB1 polymorphism was significantly associated with susceptibility to GD with a codominant mode of inheritance (P ¼ 0.00005; OR ¼ 1.37 (1.18-1.60)). No association with GD was found in Japanese cohort. However, subgroup analysis in Japanese GD patients revealed a correlation between the NFKB1genotype and the development of ophthalmopathy (P ¼ 0.009; OR ¼ 1.49 (1.10-2.01)), and the age of disease onset (P ¼ 0.009; OR ¼ 1.45 (1.09-1.91)). Our results suggest that NFKB1 À94ins/del ATTG polymorphism may be associated with susceptibility to and/or phenotype of GD.
Introduction
The nuclear factor-kB (NF-kB) signaling pathway regulates the expression of hundreds of genes, many of which play important roles in the immune system, such as genes encoding cytokines (IL-2, IL-6, IL-12, TNF-a, IFN-g), cytokine receptors (IL-2 receptor), cell adhesion molecules (VCAM-1, ICAM-1) and chemokines (IL-8).
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The NF-kB family of transcription factors has five members: p50/p105 (encoded by the NFKB1 gene, 4q24), p52/p100 (NFKB2, 10q24.32), RelA (RELA, 11q13.3), RelB (RELB, 19q32.2) and c-Rel (REL, 2p16.1). All these proteins share a highly conserved DNAbinding/dimerization domain called the Rel homology domain. The p50 and p52 transcription factors, which are derived from precursor proteins, p105 and p100 respectively, lack transcriptional activation domains, and their homodimers are thought to act as repressors. In contrast, RelA, RelB and c-Rel carry transcriptional activation domains. Although the p50/RelA heterodimer is the major and most active NF-kB dimer in many cells, the balance between different NF-kB homo-and heterodimers will control the level of transcriptional activity. Moreover, the activity of NF-kB signaling is tightly regulated by interaction with several inhibitory IkB proteins and by IkB kinases (IKK).
Clearly, any change in the delicate balance of the NF-kB signaling pathway can lead to an alteration in immune response. 3 Thus, genes involved in the NF-kB pathway are important candidate genes for autoimmune diseases. So far, two genes, SUMO4 and MAP3K7IP2 (6q25), have been studied in autoimmune thyroid diseases (AITD). SUMO4 encodes a protein involved in the ubiquitination of IkBa, and a single nucleotide polymorphism (SNP) causing methionine to valine substitution (rs237025, A163G, M55V) results in greater NF-kB transcriptional activity. 4 This polymorphism has been associated with susceptibility to AITD, type 1 diabetes (T1D) and rheumatoid arthritis in Asian populations. 5, 6 However, the association of M55V with Graves' disease (GD) and T1D could not be replicated in Caucasian populations, suggesting heterogeneity in the genetic effect of the SUMO4 locus among diverse ethnic groups.
7-10 MAP3K7IP2 (also known as TAB2) encodes a different inhibitor of the NF-kB signaling pathway and a SNP (001Msp) has been shown to be associated with AITD. 4, 9 Recently, a functional NFKB1 promoter polymorphism (À94ins/del ATTG) has been identified and associated with the development of ulcerative colitis. 11 In this study, we analyzed the association of this polymorphism with GD. First, we performed a population-based, casecontrol study in a Polish-Warsaw cohort. Next, replication studies have been performed in a second set of Polish-Caucasian (from Gliwice) and Japanese subjects. Finally, we analyzed the interactions between NFKB1 genotypes and other established GD susceptibility markers (HLA-DRB1*03 and CTLA-4 A49G) and the association of NFKB1 polymorphism with the clinical phenotype of GD (age of onset, sex, presence of ophthalmopathy, family history of AITD).
Results
Association of NFKB1 À94ins/del ATTG polymorphism with susceptibility to GD The initial case-control study in the Polish-Warsaw cohort had a power 40.80 to detect an association similar to the one originally reported by Karban et al. 11 at a 0.05, with one-tailed w 2 -test. We found that the frequency of the D allele (À94del ATTG) was significantly greater in GD compared to controls (46.4 vs 38.8%; P ¼ 0.0006; odds ratio (OR) ¼ 1.36 (1.14-1.63)). There were also significant differences in genotype distributions, suggesting a codominant or recessive effect (Table 1) . For a replication study, we analyzed a second set of unrelated GD patients and control subjects from the Polish-Gliwice cohort. The study confirmed a significant increase of the D allele in GD (46.2 vs 38.9%; P ¼ 0.039; OR ¼ 1.35 (1.01-1.79)), whereas the genotype distribution suggested a dominant or codominant effect. No evidence of significant heterogeneity between Warsaw and Gliwice studies has been detected. Combining all Polish GD samples and controls showed that the NFKB1 À94ins/del ATTG polymorphism was significantly (P ¼ 0.00005) associated with susceptibility to GD with a codominant mode of inheritance, producing an OR of 1.37 (1.18-1.60). Based on the genotype distribution in all Polish samples, the dominant and recessive model could be rejected (P ¼ 0.013 and P ¼ 0.023, respectively).
In addition, we analyzed the association of NFKB1 polymorphism with GD in an ethnically different group of Japanese subjects. The frequencies of D allele and DD homozygote were similar in Polish-Caucasian and Japanese control groups. No statistically significant differences in D allele (37.4 vs 39.6%; P ¼ 0.428; OR ¼ 0.91 (0.72-1.15)) or genotype frequencies were observed among cases and controls in the Japanese cohort.
Association of the NFKB1 À94ins/del ATTG polymorphism with clinical and genetic characteristics of GD The distribution of NFKB1 genotypes was compared in subgroups of GD patients stratified by clinical and genetics parameters. In Polish-Caucasian patients (the pooled Warsaw and Gliwice cohorts), there was a tendency towards an increase of D allele in the subgroup with clinically evident ophthalmopathy (49.8 vs 43.9%; P ¼ 0.058; OR ¼ 1.26 (0.99-1.61)) ( Table 2 ). The distribution of NFKB1 genotypes in GD with or without eye disease suggested a codominant (P ¼ 0.056; OR ¼ 1.27 (0.99-1.63)) or recessive model (P ¼ 0.035; OR ¼ 1.56 (1.03-2.36)). The NFKB1 genotypes were equally distributed among HLA-DRB1*03 and CTLA-4 49G alleles carriers. Moreover, no significant interaction between CTLA-4 CT60, PTPN22 C1858T and NFKB1 polymorphism was detected in the Polish-Warsaw cohort (data not shown).
In Japanese GD patients we observed a significant association of the NFKB1 polymorphism with the development of clinically evident ophthalmopathy ( Table 3 Next, we applied multiple logistic regression analysis to adjust for effects of other factors on the development of ophthalmopathy in Polish-Caucasian and Japanese populations ( Table 4 ). The independent variables included in the model were: NFKB1 genotypes, disease onset, tobacco smoking and male sex. In Caucasians population, we found a statistically significant effect of the NFKB1 genotype under the recessive model and a trend for an effect assuming a codominant model. Analysis of other variables showed a strong effect of cigarette smoking and older age of onset. In the Japanese cohort, only the NFKB1 polymorphism had a statistically significant effect on the development of ophthalmopathy under all three models considered although the data suggested that the codominant model may be most appropriate.
Discussion
The NFKB1 promoter À94ins/del ATTG polymorphism was first reported by Karban et al. 11 to be linked to and associated with susceptibility to ulcerative colitis (UC) in a non-Jewish, North American-Caucasian population. Although the authors suggested a recessive effect, we found that the most significant genotype effect was actually present under a codominant model (P ¼ 0.004, OR ¼ 1.30 (1.09-1.56)). Additionally, in vitro functional assays suggested that the D allele may result in reduced gene expression and hence decreased p50/p105 NF-kB protein production. The authors hypothesized that (i) a decrease in p50 homodimers may result in a relative overexpression of Rel homo-and heterodimers, or (ii) low levels of p50 lead to a poor innate immune response.
11 Table 2 Abbreviations: CI, confidence interval; GD, Graves' disease; OR, odds ratio. P-values and odds ratios (OR) were calculated for codominant model.
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The association of the NFKB1 polymorphism with UC has been replicated in an independent study in a Dutch population. 12 Moreover, a significant genotype-phenotype correlation was identified-mean age of disease onset was significantly lower in patients homozygous for the D allele. 12 However, the association of À94ins/del ATTG polymorphism with susceptibility to or phenotype of UC could not be replicated in German, UK and Spanish populations. [13] [14] [15] The discrepancies between these studies may be explained by differences in environmental factors for UC in different populations and/or differences in the haplotypic context of the À94 del ATTG variant among the studied populations.
The NFKB1 À94ins/del ATTG polymorphism was not studied in detail in other autoimmune diseases, although there are single reports in which no associations with rheumatoid arthritis, systemic lupus erythematosus, celiac disease or T1D were found. [16] [17] [18] However, one study reported an epistatic interaction between NFKB1 and Fc receptor-like 3 (FCRL3) gene in Spanish-Caucasian patients with rheumatoid arthritis. 19 Interestingly, FCRL3 has been recently associated with susceptibility to GD. 9, 20 A different (CA) repeat polymorphism located in the 3 0 region of NFKB1 has been reported to be associated with T1D but subsequent studies were unable to confirm this finding. [21] [22] [23] In this study, the frequency of the D allele in control populations were similar to those observed in other Caucasian populations, as reported by Karban . [11] [12] [13] First in the Warsaw cohort, we observed an increased frequency of the D allele in GD patients compared to controls. This observation was replicated in a second, independent set of Polish GD cases and healthy controls. The results from both Polish cohorts suggest a codominant effect. However, the association with susceptibility to GD was not confirmed in a different ethnic population-Japanese. Although a potential functional variant could be expected to be associated with a disease independent of ethnicity, this is not always so, even for established associations such as SUMO4.
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Search for genotype-phenotype correlations revealed a trend tendency towards an increase of D allele in PolishCaucasian patients with Graves' ophthalmopathy. Consistent with this finding, in Japanese GD patients the NFKB1 polymorphism was significantly associated with clinically evident eye disease. Among Japanese we also found a correlation between the NFKB1-94del ATTG allele and younger age of onset. These results are interesting given the established role of NF-kB in pathogenesis of ophthalmopathy. Several proinflammatory cytokines (IL-1, TNF-a and IFN-g), which are associated with the NF-kB signaling pathway, are known to play a central role in the autoimmune inflammation in orbital tissues. 24, 25 Apart from leukocyte activation, NFkB plays an important role in glycosaminoglycans production by orbital fibroblast. 26 Therefore, the treatment of Graves' ophthalmopathy with glucocorticoids is predominantly directed against the NF-kB signaling pathway. 27, 28 To analyze further the effect of NFKB1 vs other environmental and demographic factors on the development of eye symptoms, we applied multiple logistic regression analysis. In both cohorts the NFKB1 polymorphism increased the risk of developing eye disease. In addition, we confirmed the strong association of cigarette smoking and older age of onset of GD with ophthalmopathy in Polish-Caucasian patients. 29 Apart from NFKB1 genotypes, no other variables had a significant effect on the development of ophthalmopathy in Japanese GD patients, confirming our previous results. 30 Thus, the predisposing factors to ophthalmopathy in Japanese population remain to be established.
Finally, some limitations of our study need to be pointed out: (i) before accepting as proven the association of NFKB1 À94ins/del ATTG with GD should be further replicated in other Caucasian populations; (ii) À94ins/del ATTG may be linked to other functional Table 4 Analysis by multiple logistic regression of an association between NFKB1 À94ins/del ATTG promoter genotypes and Graves' ophthalmopathy after adjustment for age at onset, smoking status and sex NFKB1 promoter polymorphism in Graves' disease A Kurylowicz et al polymorphisms within the NFKB1 locus and defining 'haplotype blocks' by analyzing more markers in the region may be necessary to delineate the primary association and explain differences between populations; 31 (iii) genotype-phenotype correlation results should be regarded as preliminary since the analysis was underpowered, which may result in both, falsenegative and -positive results-thus the association with clinically apparent ophthalmopathy also requires replication.
In conclusion, our results indicate that the NFKB1 polymorphism may be associated with susceptibility to and/or phenotype of GD.
Patients and methods

Subjects
The following cohorts of patients and controls were studied: (i) Poland-Warsaw, comprising of 388 GD patients and 688 healthy subjects; (ii) Poland-Gliwice, comprising of 198 GD patients and 194 healthy subjects and (iii) Japan-Kurume, comprising of 424 GD patients and 222 healthy subjects.
Patients with GD were consecutive series of unrelated cases from the Department of Endocrinology, Medical University of Warsaw; Department of Nuclear Medicine and Endocrine Oncology, Institute of Oncology in Gliwice and Department of Endocrinology, Kurume University School of Medicine. The clinical characteristics of the studied groups are shown in Table 5 . The diagnosis of GD was based on clinical and biochemical symptoms of hyperthyroidism and was confirmed by the presence of diffuse goiter, detectable TSH receptor auto antibodies (TRAK Lumitest, BRAHMS Diagnostica GmbH, Germany) and/or increased radioiodine uptake. The severity of ophtalmopathy was assessed according to the NOSPECS classification. Patients with proptosis (NOSPECS class III), extraocular muscle dysfunction (class IV), exposure keratitis (class V) and optic neuropathy (class VI) were considered clinically evident. The control group comprised of ethnically matched healthy subjects, who had no family history of autoimmune diseases. The research program was approved by the Local Ethical Committees, and written informed consent was obtained from all of the participants.
Genotyping
Genotyping of the NFKB1 À94ATTG ins/del promoter polymorphism (GeneBank accession AF213884, gi 7012904) was determined by PCR amplification (primers: 5 0 -TTTAATCTGTGAAGAGATGTGAATG-3 0 and 5 0 -CTCTGGCTTCCTAGCAGGG-3 0 ), followed by digestion with the restriction enzyme Van91I (Fermentas International Inc., Ontario, Canada), as described by Karban et al. 11 The obtained restriction fragments were visualized on a 2% agarose gel. To confirm the accuracy of the method employed, all heterozygotes were analyzed twice by RFLP and randomly selected subjects were analyzed by direct sequencing. Replication studies in Gliwice and Kurume have been performed blinded to initial results obtained in Warsaw. Analysis of CTLA-4 and HLA-DRB1 polymorphisms were reported previously. 32, 33 Statistical analysis Allele frequencies were compared between groups by w 2 test on a 2 Â 2 contingency table using Statistica software package (StatSoft Inc., Tulsa, OK, USA). The genotype distribution was analyzed assuming three models of inheritance: dominant, codominant or recessive. Under each model the OR with 95% confidence interval and the P-value for an association was calculated. Also, the fit of the model was assessed by a w 2 -test. These calculations were performed using Web-Assotest program (available at: http://www.ekstroem.com/assotest/assotest.html). P-values less than 0.05 were considered significant. The conservative Bonferoni's correction for multiple testing was not applied. 34 Homogeneity of OR across the population strata was assessed with Breslow-Day test (dominant or recessive model) or multiple logistic regression (codominant model) using SPSS software package (SPSS Inc. Chicago, IL, USA). In the analysis by logistic regression, the NFKB1 genotype was encoded Age of onset and disease duration are presented as mean7s.d.
NFKB1 promoter polymorphism in Graves' disease A Kurylowicz et al as 0, 1, or 2 according to the number of alleles with the À94ATTG deletion and the homogeneity of OR was assessed by analyzing the statistical significance of an interaction between population and genotype by the likelihood ratio test. 35 Multiple logistic regression was also used to analyze the association between the NFKB1 genotypes and Graves' ophthalmopathy after adjustment for age at onset, smoking status and sex.
Differences in distribution of age of disease onset were analyzed by a non-parametric Mann-Whitney test. All the cases and controls in studied cohorts were in HardyWeinberg equilibrium.
